WallStSmart

Alterity Therapeutics Ltd (ATHE)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 990919% more annual revenue ($65.77B vs $6.64M). MRK leads profitability with a 13.6% profit margin vs -219.9%. MRK earns a higher WallStSmart Score of 50/100 (D+).

ATHE

Avoid

26

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: 0.32

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ATHE.

MRKSignificantly Overvalued (-48.8%)

Margin of Safety

-48.8%

Fair Value

$80.79

Current Price

$118.72

$37.93 premium

UndervaluedFair: $80.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATHE3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
74.6%10/10

Revenue surging 74.6% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$280.20B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

ATHE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$88.31M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-46.4%2/10

ROE of -46.4% — below average capital efficiency

Altman Z-ScoreHealth
0.322/10

Distress zone — elevated risk

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.0x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ATHE

The strongest argument for ATHE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 74.6% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : ATHE

The primary concerns for ATHE are EPS Growth, Market Cap, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

ATHE profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

ATHE is growing revenue faster at 74.6% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alterity Therapeutics Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?